Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanreqing Capsule in Mild and Common COVID-19
NCT05305456Phase 3Completed
- Sponsor
- Jiangsu Famous Medical Technology
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Tanreqing Capsules in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Jiangsu Famous Medical Technology. Primary endpoint: The time from the first dose to sustained clinical recovery at 8 days. Started Mar 2022; status: completed.
02
Drugs
Tanreqing Capsules
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05305456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305456.